ICU · SeaStar Medical Holding Corp
$3.77
+0.03 (+0.80%)
At close · Jul 24
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company does *not* believe that its cash on hand will be sufficient to enable it to fund its operations, including clinical trial expenses and capital expenditure requirements for at least *12* months from the issuance of these unaudited condensed consolidated financial statements. The Company believes that these conditions raise substantial doubt about its ability to continue as a going concern.”View the 10-Q filed May 13, 2026
Market Cap
$14.99M
Shares
4.00M
SeaStar Medical Holding Corp Earnings Call Transcripts
Every quarterly earnings call for SeaStar Medical Holding Corp (ICU) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
Earnings call
FY26 · Q2
2026-06-30
SeaStar Medical Holding Corp Q2 FY2026 Earnings Call
Confident tone
QUELIMMUNE pediatric commercial adoption
NEUTRALIZE-AKI pivotal trial enrollment
Adult AKI market opportunity and FDA pathway
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
SeaStar Medical Holding Corp Q1 FY2026 Earnings Call
Confident tone
Quellimmune pediatric commercial momentum
Neutralize AKI pivotal trial enrollment
SCD platform broader indications
Revenue
$495,000
▲ 68.9% YoY Gross margin
90.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
SeaStar Medical Holding Corp Q4 FY2025 Earnings Call
Confident tone
Pediatric AKI Commercial Expansion (Qualimmune)
Neutralize AKI Pivotal Trial Enrollment (Adult AKI)
SAVE Registry Publication and Clinical Evidence
Revenue
$420,000*
▲ 526.9% YoY Gross margin
97.1%
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
SeaStar Medical Holding Corp Q3 FY2025 Earnings Call
Confident tone
Neutralize AKI pivotal trial enrollment
Quellimmune commercial launch and pediatric site activation
Neutralize CRS cardiorenal syndrome trial
Revenue
$183,000
▲ 169.1% YoY Gross margin
92.3%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
SeaStar Medical Holding Corp Q1 FY2025 Earnings Call
Confident tone
QUELIMMUNE pediatric commercial launch
NEUTRALIZE-AKI adult pivotal trial
Cardiac surgery breakthrough device designations
Revenue
$293,000
Diluted EPS
$-4.40
Gross margin
100.0%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
SeaStar Medical Holding Corp Q4 FY2024 Earnings Call
Revenue
$67,000*
Gross margin
100.0%
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-12-04
SeaStar Medical Holding Corp Q3 FY2024 Earnings Call
Revenue
$68,000
Diluted EPS
$-11.00
Gross margin
100.0%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-15
SeaStar Medical Holding Corp Q2 FY2023 Earnings Call
Diluted EPS
$-41.00
Audio
Transcript
Slides
8-K10-Q
Showing 1–8 of 8 earnings calls